OBJECTIVE: To investigate the accuracy of Medical Benefit Schedule (MBS) item numbers to identify treatments for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC). METHODS: We linked records from QSkin Study participants (n=37,103) to Medicare. We measured the proportion of Medicare claims for primary excision of BCC/SCC that had corresponding claims for histopathology services. In subsets of participants, we estimated the sensitivity and external concordance of MBS item numbers for identifying BCC/SCC diagnoses by comparing against 'gold-standard' histopathology reports. RESULTS: A total of 2,821 (7.6%) participants had 4,830 separate Medicare claims for BCC/SCC excision; almost all (97%) had contemporaneous Medicare claims for histopathology services. Among participants with BCC/SCC confirmed by histology reports, 76% had a corresponding Medicare claim for primary surgical excision of BCC/SCC. External concordance for Medicare claims for primary BCC/SCC excision was 68%, increasing to 97% when diagnoses for intra-epidermal carcinomas and keratoacanthomas were included. CONCLUSIONS: MBS item numbers for primary excision of BCC/SCC are reasonably reliable for determining incident cases of keratinocyte skin cancers, but may underestimate incidence by up to 24%. IMPLICATIONS: Medicare claims data may have utility in monitoring trends in conditions for which there is no mandatory reporting.
OBJECTIVE: To investigate the accuracy of Medical Benefit Schedule (MBS) item numbers to identify treatments for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC). METHODS: We linked records from QSkin Study participants (n=37,103) to Medicare. We measured the proportion of Medicare claims for primary excision of BCC/SCC that had corresponding claims for histopathology services. In subsets of participants, we estimated the sensitivity and external concordance of MBS item numbers for identifying BCC/SCC diagnoses by comparing against 'gold-standard' histopathology reports. RESULTS: A total of 2,821 (7.6%) participants had 4,830 separate Medicare claims for BCC/SCC excision; almost all (97%) had contemporaneous Medicare claims for histopathology services. Among participants with BCC/SCC confirmed by histology reports, 76% had a corresponding Medicare claim for primary surgical excision of BCC/SCC. External concordance for Medicare claims for primary BCC/SCC excision was 68%, increasing to 97% when diagnoses for intra-epidermal carcinomas and keratoacanthomas were included. CONCLUSIONS:MBS item numbers for primary excision of BCC/SCC are reasonably reliable for determining incident cases of keratinocyte skin cancers, but may underestimate incidence by up to 24%. IMPLICATIONS: Medicare claims data may have utility in monitoring trends in conditions for which there is no mandatory reporting.
Authors: A Stang; L Khil; H Kajüter; N Pandeya; C D Schmults; E S Ruiz; P S Karia; A C Green Journal: J Eur Acad Dermatol Venereol Date: 2019-12 Impact factor: 6.166
Authors: Upekha E Liyanage; Matthew H Law; Xikun Han; Jiyuan An; Jue-Sheng Ong; Puya Gharahkhani; Scott Gordon; Rachel E Neale; Catherine M Olsen; Stuart MacGregor; David C Whiteman Journal: Hum Mol Genet Date: 2019-09-15 Impact factor: 6.150
Authors: Bridie S Thompson; Sam Hardy; Nirmala Pandeya; Jean Claude Dusingize; Adele C Green; Athon Millane; Daniel Bourke; Ronald Grande; Cameron D Bean; Catherine M Olsen; David C Whiteman Journal: JCO Clin Cancer Inform Date: 2020-08